keyword
MENU ▼
Read by QxMD icon Read
search

I DPP 4

keyword
https://www.readbyqxmd.com/read/28207538/comparison-of-baseline-characteristics-and-clinical-course-in-japanese-patients-with-type-2-diabetes-among-whom-different-types-of-oral-hypoglycemic-agents-were-chosen-by-diabetes-specialists-as-initial-monotherapy-jddm-42
#1
Kazuya Fujihara, Risa Igarashi, Satoshi Matsunaga, Yasuhiro Matsubayashi, Takaho Yamada, Hiroki Yokoyama, Shiro Tanaka, Hitoshi Shimano, Hiroshi Maegawa, Katsuya Yamazaki, Koichi Kawai, Hirohito Sone
Little is known about the relationships between patient factors and the antihyperglycemic agents that have been prescribed as initial therapy by diabetes specialists for patients with type 2 diabetes. Moreover, there has been little clarification of the subsequent usage patterns and related factors that influenced the continuation or discontinuation of the drug or the addition of another drug. To provide information on these issues, we evaluated the clinical characteristics of Japanese patients with type 2 diabetes for whom different types of oral hypoglycemic agents (i...
February 2017: Medicine (Baltimore)
https://www.readbyqxmd.com/read/28183314/dpp-4-inhibition-has-no-acute-effect-on-bnp-and-its-n-terminal-pro-hormone-measured-by-commercial-immune-assays-a-randomized-cross-over-trial-in-patients-with-type-2-diabetes
#2
Gian Paolo Fadini, Benedetta Maria Bonora, Mattia Albiero, Martina Zaninotto, Mario Plebani, Angelo Avogaro
BACKGROUND: Use of dipeptidyl peptidase-4 inhibitors (DPP4-i) for the treatment of type 2 diabetes (T2D) has been associated with a possible increase in the risk for heart failure (HF). B-type natriuretic peptide (BNP), which is both a biomarker of HF and a hemodynamically active hormone, is a substrate of DPP-4. We herein tested the acute effects of the DPP-4i linagliptin on BNP and NT-proBNP in a cross-over placebo-controlled trial in patients with T2D with and without chronic kidney disease (CKD)...
February 10, 2017: Cardiovascular Diabetology
https://www.readbyqxmd.com/read/28182722/hemoglobin-glycation-index-as-a-useful-predictor-of-therapeutic-responses-to-dipeptidyl-peptidase-4-inhibitors-in-patients-with-type-2-diabetes
#3
Yu-Wei Chen, Jun-Sing Wang, Wayne H-H Sheu, Shih-Yi Lin, I-Te Lee, Yuh-Min Song, Chia-Po Fu, Chia-Lin Lee
INTRODUCTION: A high hemoglobin glycation index (HGI) and glycated hemoglobin (HbA1c) level are associated with greater inflammatory status, and dipeptidyl peptidase-4 (DPP-4) inhibitors can suppress inflammation. We aimed to evaluate the relationship between HGI and the therapeutic effect of DPP-4 inhibitors. METHODS: This retrospective cohort study followed 468 patients with type 2 diabetes receiving DPP-4 inhibitor treatment for 1 year. Estimated HbA1c was calculated using a linear regression equation derived from another 2969 randomly extracted patients with type 2 diabetes based on fasting plasma glucose (FPG) level...
2017: PloS One
https://www.readbyqxmd.com/read/28160554/pharmacogenetics-of-dipeptidyl-peptidase-4-inhibitors-in-a-taiwanese-population-with-type-2-diabetes
#4
Wen-Ling Liao, Wen-Jane Lee, Ching-Chu Chen, Chieh Hsiang Lu, Chien-Hsiun Chen, Yi-Chun Chou, I-Te Lee, Wayne H-H Sheu, Jer-Yuarn Wu, Chi-Fan Yang, Chung-Hsing Wang, Fuu-Jen Tsai
Dipeptidyl peptidase-4 (DPP-4) inhibitors are oral anti-hyperglycemic drugs enabling effective glycemic control in type 2 diabetes (T2D). Despite DPP-4 inhibitors' advantages, the patients' therapeutic response varies. In this retrospective cohort study, 171 Taiwanese patients with T2D were classified as sensitive or resistant to treatment based on the mean change in HbA1c levels. Using an assumption-free genome-wide association study, 45 single nucleotide polymorphisms (SNPs) involved in the therapeutic response to DPP-4 inhibitors (P < 1 × 10-4) were identified at or near PRKD1, CNTN3, ASK, and LOC10537792...
February 1, 2017: Oncotarget
https://www.readbyqxmd.com/read/28150162/workplace-interventions-to-prevent-type-2-diabetes-mellitus-a-narrative-review
#5
REVIEW
Dina Hafez, Allison Fedewa, Margaret Moran, Matthew O'Brien, Ronald Ackermann, Jeffrey T Kullgren
PURPOSE OF REVIEW: This study aims to summarize the recent peer-reviewed literature on workplace interventions for prevention of type 2 diabetes mellitus (T2DM), including studies that translate the Diabetes Prevention Program (DPP) curriculum to workplace settings (n = 10) and those that use different intervention approaches to achieve the specific objective of T2DM prevention among employees (n = 3). RECENT FINDINGS: Weight reduction was achieved through workplace interventions to prevent T2DM, though such interventions varied substantially in their effectiveness...
February 2017: Current Diabetes Reports
https://www.readbyqxmd.com/read/28142080/new-copper-i-and-heteronuclear-copper-i-ruthenium-ii-complexes-synthesis-structural-characterization-and-cytotoxicity
#6
João Lopes, David Alves, Tânia S Morais, Paulo J Costa, M Fátima M Piedade, Fernanda Marques, Maria J Villa de Brito, M Helena Garcia
A new family of copper(I) complexes of general formula [Cu(dppe)(NN)](+) have been synthesized and fully characterized, with dppe=1.2-bis(diphenylphosphino)ethane and NN representing several bidentate heteroaromatic ligands: 2,2'-bipy=2.2'-bipyridine (1), Me2bpy=4.4'-dimethyl-2,2'-bipyridine (2), dpytz=3-(2-pyridyl)-5,6-diphenyl-1,2,4-triazine (3), dpp=2.3-bis(2-pyridyl)pyrazine (4), and the metallaligand [Ru(η(5)-C5H5)(PPh3)(dpp)](+) (5), yielding the bimetallic copper(I)-ruthenium(II) complex [Cu(dppe)(μ-dpp)Ru(η(5)-C5H5)(PPh3)](2+) (6)...
January 23, 2017: Journal of Inorganic Biochemistry
https://www.readbyqxmd.com/read/28127851/impact-of-insulin-sensitivity-beta-cell-function-and-glycemic-control-on-initiation-of-second-line-glucose-lowering-treatment-in-newly-diagnosed-type-2-diabetes
#7
Wolfgang Rathmann, Klaus Strassburger, Brenda Bongaerts, Pavel Bobrov, Oliver Kuss, Karsten Müssig, Daniel F Markgraf, Julia Szendroedi, Christian Herder, Michael Roden
AIMS: The aim was to investigate whether insulin sensitivity, beta-cell function or glycemic control at diagnosis predict initiation of second-line treatment in newly diagnosed type 2 diabetes. MATERIAL AND METHODS: Type 2 diabetes patients (n = 138) on initial metformin monotherapy (age [mean ± SD]: 52 ± 10 years; 67% males; BMI: 32 ± 6 kg/m(2) ) from the prospective German Diabetes Study cohort (n = 398) were included. Patients remained under treatment of their general practitioners, yet underwent detailed metabolic characterization after diabetes diagnosis for study purposes (hyperinsulinemic-euglycemic clamp: M value; i...
January 27, 2017: Diabetes, Obesity & Metabolism
https://www.readbyqxmd.com/read/28116795/novel-oral-glucose-lowering-drugs-compared-to-insulin-are-associated-with-lower-risk-of-all-cause-mortality-cardiovascular-events-and-severe-hypoglycemia-in-type-2-diabetes-patients
#8
Thomas Nyström, Johan Bodegard, David Nathanson, Marcus Thuresson, Anna Norhammar, Jan W Eriksson
AIMS: To investigate the association of novel oral glucose lowering drugs (GLDs) compared with insulin to risk of all-cause mortality, cardiovascular disease (CVD) and severe hypoglycaemia. METHODS: During 2013-2014 all type 2 diabetes patients in Sweden identified as new users of novel oral GLDs, i.e. either dipeptidyl-peptidase-4 inhibitors (DPP-4i) or sodium glucose cotransporter-2 inhibitors (SGLT-2i; only dapagliflozin available in Sweden during the study period), compared to insulin treatment in the Prescribed Drug Register were included and followed in the Patient- and Cause of Death Registers...
January 24, 2017: Diabetes, Obesity & Metabolism
https://www.readbyqxmd.com/read/28094135/diabetes-prevention-program-translation-in-the-veterans-health-administration
#9
Tannaz Moin, Laura J Damschroder, Mona AuYoung, Matthew L Maciejewski, Santanu K Datta, Jane E Weinreb, Nanette I Steinle, Charles Billington, Maria Hughes, Fatima Makki, Robert G Holleman, H Myra Kim, Amy S Jeffreys, Linda S Kinsinger, Jennifer A Burns, Caroline R Richardson
INTRODUCTION: This clinical demonstration trial compared the effectiveness of the Veterans Affairs Diabetes Prevention Program (VA-DPP) with an evidence-based usual care weight management program (MOVE!(®)) in the Veterans Health Administration health system. DESIGN: Prospective, pragmatic, non-randomized comparative effectiveness study of two behavioral weight management interventions. SETTING/PARTICIPANTS: Obese/overweight Veterans with prediabetes were recruited from three geographically diverse VA sites between 2012 and 2014...
January 13, 2017: American Journal of Preventive Medicine
https://www.readbyqxmd.com/read/28091829/inhibition-of-dpp-4-activity-and-neuronal-atrophy-with-genistein-attenuates-neurological-deficits-induced-by-transient-global-cerebral-ischemia-and-reperfusion-in-streptozotocin-induced-diabetic-mice
#10
Mithun Singh Rajput, Purnima Dey Sarkar, Nilesh Prakash Nirmal
Genistein, an isoflavonoid phytoestrogen, has been known for its potential pharmacological properties especially for neuroprotection and treating diabetes. The present study aims to determine the neuroprotective efficacy of genistein against global cerebral ischemia-reperfusion-induced neuronal injury in streptozotocin-induced diabetic mice and explore the underlying mechanisms. Streptozotocin-induced diabetic mice were subjected to transient cerebral ischemia by occluding both common carotid arteries for 30 min followed by 24 h reperfusion to induce neuronal injury...
January 16, 2017: Inflammation
https://www.readbyqxmd.com/read/27972229/the-incidence-of-hypoglycemia-in-type-ii-diabetes-mellitus-t2dm-patients-treated-with-insulin-therapy-in-combination-with-dpp-4-in-greece-a-sub-analysis-of-hypo-2-study
#11
I Yfantopoulos, P Katopodis, G Rombopoulos, A Yallouridis, A Chantzaras, E Kossiva, C Varounis
No abstract text is available yet for this article.
November 2016: Value in Health: the Journal of the International Society for Pharmacoeconomics and Outcomes Research
https://www.readbyqxmd.com/read/27859701/uterine-infection-with-bovine-herpesvirus-type-4-in-dairy-cows
#12
S Klamminger, I Prunner, M J Giuliodori, M Drillich
Diseases of the reproductive tract are a frequent problem in dairy herds. Herpesviruses are uterine pathogens also involved in other clinical diseases; for example, bovine herpesvirus type 4 BoHV-4 induces abortion, enteritis, metritis, pneumonia and vaginitis, but it can also be detected in healthy cows. The role of BoHV-4 in the development of clinical endometritis (CE) or subclinical endometritis (SE) has not clearly been described. Therefore, the objective of this study was to describe the prevalence of uterine BoHV-4 infection and its relationship with clinical, bacteriological and cytological findings in dairy cows 20-30 days after calving...
November 14, 2016: Reproduction in Domestic Animals, Zuchthygiene
https://www.readbyqxmd.com/read/27848150/factors-related-to-the-glucose-lowering-efficacy-of-dipeptidyl-peptidase-4-inhibitors-a-systematic-review-and-meta-analysis-focusing-on-ethnicity-and-study-regions
#13
REVIEW
Kayo Fujita, Masayuki Kaneko, Mamoru Narukawa
BACKGROUND AND OBJECTIVE: Several systematic reviews and meta-analyses have been conducted including an analysis to investigate the difference between ethnic groups in the glucose-lowering efficacy of dipeptidyl peptidase-4 (DPP-4) inhibitors. This study assessed the factors related to the glucose-lowering efficacy and explored potential differences among ethnicities; in particular, Japanese subjects were dealt separately from other Asian subjects. METHODS: A systematic literature search was conducted using the MEDLINE, EMBASE, Cochrane Central Register, Japan Medical Abstracts Society, and ClinicalTrials...
November 16, 2016: Clinical Drug Investigation
https://www.readbyqxmd.com/read/27835680/benefits-and-harms-of-sodium-glucose-co-transporter-2-inhibitors-in-patients-with-type-2-diabetes-a-systematic-review-and-meta-analysis
#14
Heidi Storgaard, Lise L Gluud, Cathy Bennett, Magnus F Grøndahl, Mikkel B Christensen, Filip K Knop, Tina Vilsbøll
OBJECTIVE: Sodium-glucose co-transporter 2 inhibitors (SGLT2-i) are a novel drug class for the treatment of diabetes. We aimed at describing the maximal benefits and risks associated with SGLT2-i for patients with type 2 diabetes. DESIGN: Systematic review and meta-analysis. DATA SOURCES AND STUDY SELECTION: We included double-blinded, randomised controlled trials (RCTs) evaluating SGLT2-i administered in the highest approved therapeutic doses (canagliflozin 300 mg/day, dapagliflozin 10 mg/day, and empagliflozin 25 mg/day) for ≥12 weeks...
2016: PloS One
https://www.readbyqxmd.com/read/27809848/impact-of-glycemic-control-with-sitagliptin-on-the-2-year-progression-of-arterial-stiffness-a-sub-analysis-of-the-prologue-study
#15
RANDOMIZED CONTROLLED TRIAL
Hirofumi Tomiyama, Takashi Miwa, Kenshi Kan, Munehide Matsuhisa, Haruo Kamiya, Mamoru Nanasato, Tomoki Kitano, Hiroaki Sano, Jun Ohno, Masato Iida, Masataka Sata, Hirotsugu Yamada, Koji Maemura, Atsushi Tanaka, Toyoaki Murohara, Koichi Node
BACKGROUND: No conclusive evidence has been obtained yet on the significance of the effects of dipeptidyl peptidase-4 (DPP-4 inhibitor) treatment on the arterial stiffness in clinical settings. In addition, the effects of good glycemic control on the arterial stiffness have also not been clarified yet. As a sub-analysis of the PROLOGUE study, we examined the effect of a DPP-4 inhibitor (sitagliptin) on the 2-year progression of the arterial stiffness and also to determine the effect of good glycemic control on the rate of progression of the arterial stiffness...
3, 2016: Cardiovascular Diabetology
https://www.readbyqxmd.com/read/27800649/effects-of-dpp-4-inhibitor-linagliptin-and-glp-1-receptor-agonist-liraglutide-on-physiological-response-to-hypoglycemia-in-japanese-subjects-with-type-2-diabetes-a-randomized-open-label-2-arm-parallel-comparative-exploratory-trial
#16
Daisuke Yabe, Takashi Eto, Masanari Shiramoto, Shin Irie, Kenta Murotani, Yusuke Seino, Hitoshi Kuwata, Takeshi Kurose, Susumu Seino, Bo Ahren, Yutaka Seino
Dipeptidyl peptidase-4 (DPP-4) inhibitors reduces the risk of hypoglycemia, possibly through augmentation of glucose-dependent insulinotropic polypeptide (GIP) action but not that of glucagon-like peptide-1 (GLP-1) on glucagon secretion. To examine this model in Japanese individuals with type 2 diabetes (T2D), the effects of the DPP-4 inhibitor linagliptin on glucagon and other counterregulatory hormone responses to hypoglycemia were evaluated and compared with those of the GLP-1 receptor agonist liraglutide in a multi-center, randomized, open-label, 2 arm parallel comparative, exploratory trial...
November 1, 2016: Diabetes, Obesity & Metabolism
https://www.readbyqxmd.com/read/27784733/comprehensive-analysis-of-established-dyslipidemia-associated-loci-in-the-diabetes-prevention-program
#17
Tibor V Varga, Alexandra H Winters, Kathleen A Jablonski, Edward S Horton, Prajakta Khare-Ranade, William C Knowler, Santica M Marcovina, Frida Renström, Karol E Watson, Ronald Goldberg, José C Florez, Toni I Pollin, Paul W Franks
BACKGROUND: We assessed whether 234 established dyslipidemia-associated loci modify the effects of metformin treatment and lifestyle intervention (versus placebo control) on lipid and lipid subfraction levels in the Diabetes Prevention Program randomized controlled trial. METHODS AND RESULTS: We tested gene treatment interactions in relation to baseline-adjusted follow-up blood lipid concentrations (high-density lipoprotein [HDL] and low-density lipoprotein-cholesterol, total cholesterol, and triglycerides) and lipoprotein subfraction particle concentrations and size in 2993 participants with pre-diabetes...
December 2016: Circulation. Cardiovascular Genetics
https://www.readbyqxmd.com/read/27780736/add-on-therapy-with-anagliptin-in-japanese-patients-with-type-2-diabetes-mellitus-treated-with-metformin-and-miglitol-can-maintain-higher-concentrations-of-biologically-active-glp-1-total-gip-and-a-lower-concentration-of-leptin
#18
Takeshi Osonoi, Miyoko Saito, Natsuyo Hariya, Moritaka Goto, Kazuki Mochizuki
Metformin, α-glucosidase inhibitors (α-GIs), and dipeptidyl peptidase 4 inhibitors (DPP-4Is) reduce hyperglycemia without excessive insulin secretion, and enhance postprandial plasma concentration of glucagon-like peptide-1 (GLP-1) in type-2 diabetes mellitus (T2DM) patients. We assessed add-on therapeutic effects of DPP-4I anagliptin in Japanese T2DM patients treated with metformin, an α-GI miglitol, or both drugs on postprandial responses of GLP-1 and glucose-dependent insulinotropic polypeptide (GIP), and on plasma concentration of the appetite-suppressing hormone leptin...
December 2016: Peptides
https://www.readbyqxmd.com/read/27779433/patient-preferences-for-diabetes-treatment-attributes-and-drug-classes
#19
Emuella M Flood, Kelly F Bell, Marie C de la Cruz, France M Ginchereau-Sowell
OBJECTIVE: To identify which treatment attributes are most influential in determining patient preferences for diabetes treatments and explore patient preferences for diabetes drug classes. RESEARCH DESIGN AND METHODS: US adults with type 1 or type 2 diabetes completed an online adaptive conjoint analysis survey. The survey examined 14 attributes, including efficacy, regimen, and risk of common side effects and rare but serious adverse events. Respondents selected between hypothetical treatments with different attributes...
February 2017: Current Medical Research and Opinion
https://www.readbyqxmd.com/read/27514514/continued-efforts-to-translate-diabetes-cardiovascular-outcome-trials-into-clinical-practice
#20
REVIEW
Angelo Avogaro, Gian Paolo Fadini, Giorgio Sesti, Enzo Bonora, Stefano Del Prato
Diabetic patients suffer from a high rate of cardiovascular events and such risk increases with HbA1c. However, lowering HbA1c does not appear to yield the same benefit on macrovascular endpoints, as observed for microvascular endpoints. As the number of glucose-lowering medications increases, clinicians have to consider several open questions in the management of type 2 diabetes, one of which is the cardiovascular risk profile of each regimen. Recent placebo-controlled cardiovascular outcome trials (CVOTs) have responded to some of these questions, but careful interpretation is needed...
11, 2016: Cardiovascular Diabetology
keyword
keyword
110953
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"